Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IONIS JBI1 2.5Rx - Ionis Pharmaceuticals/Janssen Biotech

Next Previous
X
Search
Drug Profile

IONIS JBI1 2.5Rx - Ionis Pharmaceuticals/Janssen Biotech

Alternative Names: IONIS-JBI1-2.5Rx

Latest Information Update: 28 Dec 2021

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ionis Pharmaceuticals
  • Developer Ionis Pharmaceuticals; Janssen Biotech
  • Class Antisense oligonucleotides
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Autoimmune disorders

Most Recent Events

  • 28 Dec 2021 No recent reports of development identified for phase-I development in Autoimmune-disorders in USA (PO)
  • 14 Nov 2018 Phase-I clinical trials in Autoimmune disorders in USA (PO) (Ionis Pharmaceuticals pipeline, November 2018)
  • 19 Jul 2016 IONIS JBI1 2.5Rx licensed to Janssen Biotech for the treatment of Gastro-intestinal autoimmune disorders

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top